Every 424B that Inovio Pharmaceu (INO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow INO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INO filings page.
Inovio Pharmaceuticals is offering 12,500,000 shares of common stock in a combined unit with Series A and Series B warrants. Each unit (one share plus one Series A warrant and one Series B warrant) has a combined public offering price of $1.40, producing gross proceeds of $17,500,000 before underwriting discounts. Underwriting discounts total $1,050,000, leaving proceeds before expenses of $16,450,000 and estimated net proceeds of approximately $16.0 million. The offering includes a 30-day option for underwriters to purchase up to 1,875,000 additional shares and paired warrants. The Series A warrants expire one year after issuance with a $1.40 exercise price; the Series B warrants expire five years after issuance with a $1.40 exercise price. The filing states shares outstanding would be 81,496,647 after this offering (assuming no warrant exercises).
Inovio Pharmaceuticals is conducting a registered offering of common stock together with paired Series A and Series B warrants. The securities are offered in fixed combinations (one share plus one Series A warrant and one Series B warrant per unit) under a shelf registration.
The Series A warrants expire one year after issuance; the Series B warrants expire five years after issuance. Each warrant is exercisable for one share (or, in lieu, a pre-funded warrant). The filing discloses 68,996,647 shares outstanding as of December 31, 2025 and notes a public last sale price of $1.74 per share as of April 1, 2026. The prospectus supplement also summarizes Inovio’s pipeline focus, recent BLA submission for INO-3107, FDA acceptance with a PDUFA target date of October 30, 2026, and ongoing regulatory dialogue about accelerated approval eligibility.
Inovio Pharmaceuticals, Inc. filed an amendment to its prospectus supplement for a previously registered offering of 14,285,715 shares of common stock together with Series A and Series B warrants, or related pre-funded warrants. The amendment updates the terms of the outstanding Series A Warrants by extending their expiration time to 5:00 p.m. New York City time on March 31, 2026, while leaving all other warrant terms unchanged.
The company’s common stock trades on the Nasdaq Capital Market under the symbol INO, and the closing sale price was $1.51 per share on January 26, 2026. The amendment is meant to be read together with the original prospectus and its prior supplements when evaluating an investment in these securities.
Inovio Pharmaceuticals (INO) launched a primary offering of 13,158,000 shares of common stock via a prospectus supplement. The public offering price is $1.90 per share, implying gross proceeds of $25,000,200 and net proceeds of $23,500,188 after underwriting discounts and before expenses. The company granted underwriters a 30‑day option to purchase up to 1,973,700 additional shares at the public price, less discounts.
Inovio estimates approximately $23 million in net proceeds (or approximately $26.5 million if the option is exercised in full). The company plans to use the funds primarily to prepare for a potential commercial launch of INO‑3107, if approved, to advance its clinical pipeline, and for general corporate purposes. Shares outstanding were 53,571,675 as of September 30, 2025; the company states shares outstanding would be 66,729,675 immediately after this offering (or 68,703,375 if the option is fully exercised). Inovio expects that cash and this offering’s net proceeds will fund operations into the third quarter 2026.
Piper Sandler is the sole bookrunner. The Nasdaq Capital Market listing remains “INO,” and the last reported sale price on November 10, 2025 was $2.15 per share.
Inovio Pharmaceuticals launched a primary offering of common stock via a preliminary prospectus supplement under its effective shelf registration. Piper Sandler is bookrunning the deal, and the company granted the underwriters a 30‑day option to purchase additional shares at the public offering price, less discounts and commissions.
Inovio plans to use the proceeds primarily to prepare for a potential commercial launch of INO‑3107, if approved, to advance its clinical pipeline, and for general corporate purposes. The company reported that it completed submission of a Biologics License Application for INO‑3107 under the FDA’s accelerated approval program and requested priority review, targeting file acceptance by the end of 2025. Inovio’s common stock trades on Nasdaq as “INO,” and it is classified as a “smaller reporting company.”